Novavax Inc

NASDAQ:NVAXUnited States

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Contact Information

Headquarters

700 Quince Orchard RoadGAITHERSBURG, MD, United States 20878

Phone

240-268-2000

Fax

302-636-5454

Executives

Independent Chairman of the Board

James Young

President, Chief Executive Officer, Director

John Jacobs

President, Chief Operating Officer

John Trizzino

Chief Financial Officer, Executive Vice President, Treasurer

James Kelly

Executive Vice President, Chief Legal Officer, Company Secretary

Mark Casey